

Health-tech startup Longeny develops breakthrough gut microbiome test

09 December 2025 | News

Developed with scientific support from Austria-based MyBioma



Longeny, a precision-health startup advancing personalised preventive care, has now introduced truGut360™, a next-generation gut microbiome test designed to uncover the root biological imbalances fuelling today's chronic health crisis.

Developed with scientific support from Austria-based MyBioma, truGut360™ brings one of the most comprehensive microbiome analysis solutions available to Indian consumers.

For years, individuals experiencing persistent bloating, acidity, fatigue, PCOS symptoms, thyroid irregularities, autoimmune issues, weight fluctuations, or unexplained inflammation have had little clarity on underlying causes. truGut360™ changes this by analysing microbial diversity, inflammation markers, metabolic pathways, immune–gut interactions, digestion patterns, and early indicators of long-term disease risk.

Scientific evidence shows that up to 70% of the immune system and nearly 90% of metabolic activity are regulated by the gut microbiome. Global research now links gut dysbiosis to a wide spectrum of chronic issues including obesity, PCOS, diabetes, depression, hormonal imbalance, autoimmune disorders, chronic fatigue, and accelerated ageing.

truGut360™ converts this complex science into a practical at-home tool bringing lab-grade insight, once restricted to cutting-edge research facilities, directly to individuals through a simple sample and a digitally delivered precision-health report.

As chronic metabolic and lifestyle disorders rise, and as younger populations adopt proactive health behaviours, truGut360™ arrives at a defining moment for India's healthcare evolution.